MedscapeRAA Inhibitors Tied to Longer Survival With Chronic Kidney DiseaseMedscapeNEW YORK (Reuters Health) Dec 10 – Patients with chronic kidney disease (CKD) who are taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor bloc…
Johns Hopkins researchers identify a new way to predict the prognosis for … – EurekAlert (press release)
Johns Hopkins researchers identify a new way to predict the prognosis for …EurekAlert (press release)Johns Hopkins researchers have identified a new way to predict which heart failure patients are likely to see their condition get worse and which one…
CCS issues guidelines to improve early diagnosis and effective treatment of … – Medical Xpress
|
CCS issues guidelines to improve early diagnosis and effective treatment of …
Medical Xpress The Children’s Heart Failure Study Group of the Canadian Cardiovascular Society, in collaboration with the Canadian Pediatric Cardiology Association, has developed new guidelines to assist practitioners in primary care and emergency departments to … |
Dr. Reddy's Targets Roche's Rituxan in Europe: Corporate India – Businessweek
|
Dr. Reddy’s Targets Roche’s Rituxan in Europe: Corporate India
Businessweek Making a version of rituximab, the ingredient in cancer-treatment Rituxan, is where “the big opportunity is in the developed markets, clearly; that’s where the big sales are,” he said. Dr. Reddy’s joins larger rivals including Novartis AG and Pfizer … |
Physician in Thomas Trial Returns to the Stand – Patch.com
NBC Southern California |
Physician in Thomas Trial Returns to the Stand
Patch.com The chest compression and a bloodied nose choked his airways, draining oxygen from his blood and leading to brain death, Lekawa testified. Lekawa said he called Orange County prosecutors about a month after Thomas died when he read news reports … Kelly Thomas Trial update: Doctor testifies Thomas was in ‘critical’ condition …89.3 KPCC Kelly Thomas Trial – Day 6The Daily Titan |
New CLL Therapy Beats Standard Protocol – MedPage Today
|
New CLL Therapy Beats Standard Protocol
MedPage Today The findings suggest that the new drug is “equally safe yet more powerful” than rituximab, commented Jennifer Brown, MD, PhD, of the Dana-Farber Cancer Institute in Boston, who was not involved in the study but who moderated a press conference at which … |
CCS issues guidelines to improve early diagnosis & effective treatment of … – EurekAlert (press release)
|
CCS issues guidelines to improve early diagnosis & effective treatment of …
EurekAlert (press release) Philadelphia, PA, December 11, 2013 – Heart failure in children is an important cause of childhood health problems and death. The Children’s Heart Failure Study Group of the Canadian Cardiovascular Society, in collaboration with the Canadian Pediatric … |
Hyperphosphatemia in Chronic Kidney Disease – Pipeline Review, H2 2013 – SBWire (press release)
|
Hyperphosphatemia in Chronic Kidney Disease – Pipeline Review, H2 2013
SBWire (press release) ‘Hyperphosphatemia In Chronic Kidney Disease – Pipeline Review, H2 2013′, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hyperphosphatemia In Chronic Kidney Disease, … |
Data on Monoclonal Antibodies Detailed by Researchers at University Health … – HispanicBusiness.com
|
Data on Monoclonal Antibodies Detailed by Researchers at University Health …
HispanicBusiness.com By a News Reporter-Staff News Editor at Women’s Health Weekly — Fresh data on Drugs and Therapies are presented in a new report. According to news reporting from Toronto, Canada , by NewsRx journalists, research stated, “Block copolymer micelles … |
Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLL – Cancer Network
|
Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLL
Cancer Network The progression-free survival (PFS) rate at 24 weeks was 93% for patients treated with idelalisib plus rituximab compared with 46% for patients treated with rituximab alone. The median PFS of the combination arm has not yet been reached. The median PFS … Idelalisib plus rituximab extended survival in previously treated CLLHealio Gilead’s Pipeline EncouragesYahoo News |